TCGA-A2-A1G0-01A-11R-A13Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.440
- APICAL_SURFACE+0.310
- ESTROGEN_RESPONSE_EARLY+0.310
- ANDROGEN_RESPONSE+0.260
- PROTEIN_SECRETION+0.260
- TGF_BETA_SIGNALING+0.250
- BILE_ACID_METABOLISM+0.210
- NOTCH_SIGNALING+0.210
- TNFA_SIGNALING_VIA_NFKB+0.140
- KRAS_SIGNALING_UP+0.130
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- INTERFERON_ALPHA_RESPONSE-0.410
- OXIDATIVE_PHOSPHORYLATION-0.410
- MYC_TARGETS_V1-0.370
- GLYCOLYSIS-0.360
- MYC_TARGETS_V2-0.350
- PANCREAS_BETA_CELLS-0.310
- MTORC1_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.854 |
| 2 | TCGA-AC-A2FK-01A-12R-A180-07 | — | A | 0.847 |
| 3 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.822 |
| 4 | TCGA-E2-A15C-01A-31R-A12D-07 | — | A | 0.821 |
| 5 | TCGA-D8-A1XO-01A-11R-A14M-07 | — | B | 0.821 |
| 6 | TCGA-97-7938-01A-11R-2170-07 | — | cohortA1 | 0.814 |
| 7 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.812 |
| 8 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.809 |
| 9 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.805 |
| 10 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.440 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |